| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CTSO | Common Stock | Purchase | $6K | +3K | +0.68% | $2.00 | 442K | Jun 16, 2022 | Direct | F1, F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | The transactions reported on this Form 4 were open market purchases made by the reporting person pursuant to a 10b5-1 trading plan adopted by the reporting person that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. |
| F2 | Includes (a) the following restricted stock units ("RSUs") that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,100 RSUs granted on March 15, 2018, (b) 17,900 RSUs granted on February 24, 2017, (c) 54,000 RSUs granted on June 7, 2016 and (d) 125,000 RSUs granted on April 8, 2015; |
| F3 | (continued from footnote 2) (b) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: 20,739 RSUs granted on April 12, 2021 and unvested on the date hereof; and |
| F4 | (continued from footnote 3) (c) 213,806 shares of Common Stock owned by the reporting person, inclusive of the 3,000 shares purchased on June 16, 2022 and reported on this Form 4. |
President and Chief Operating Officer